Design and Development of a Novel Chalcone Derivative as an Anticholinesterase Inhibitor for Possible Treatment of Dementia
- PMID: 28687725
- PMCID: PMC5513680
- DOI: 10.12659/msm.901842
Design and Development of a Novel Chalcone Derivative as an Anticholinesterase Inhibitor for Possible Treatment of Dementia
Abstract
BACKGROUND Cognitive decline (e.g., memory loss), which mainly occurs in the elderly, is termed dementia. In the present study, we intended to explore the cholinesterase inhibitory activity of some novel synthesized chalcones, together with their effect on β-amyloid anti-aggregation. MATERIAL AND METHODS A novel class of chalcone derivatives have been synthesized and characterized by FT-IR, ¹H-NMR, ¹³C-NMR, and mass and elemental analysis. These derivatives were later used for the determination of acetylcholinesterase (AChE) inhibitory and b-amyloid anti-aggregation activity. RESULTS The results of the study showed that among the developed compounds, 8g inhibits AChE more prominently than BuChE, as suggested by a selectivity index (SI) of 2.88. Furthermore, the most potent compound, 8g, showed considerable action in inhibition of β-secretase and Aβ aggregation, but not as prominent as that of curcumin as a standard. CONCLUSIONS In conclusion, our study revealed a novel class of chalcone derivatives as a selective inhibitor of AChE with considerably action against β-secretase and Aβ aggregation. Our results may be useful in developing AD drug therapy and warrant further investigation to generate more advanced analogues.
Conflict of interest statement
The authors have declared no conflict of interest.
Figures
Similar articles
-
Design and discovery of Novel Thiazole acetamide derivatives as anticholinesterase agent for possible role in the management of Alzheimer's.Bioorg Med Chem Lett. 2016 Feb 1;26(3):747-750. doi: 10.1016/j.bmcl.2016.01.001. Epub 2016 Jan 4. Bioorg Med Chem Lett. 2016. PMID: 26783181
-
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.Eur J Med Chem. 2019 Sep 15;178:726-739. doi: 10.1016/j.ejmech.2019.06.026. Epub 2019 Jun 14. Eur J Med Chem. 2019. PMID: 31229875
-
New phosphazine and phosphazide derivatives as multifunctional ligands targeting acetylcholinesterase and β-Amyloid aggregation for treatment of Alzheimer's disease.Bioorg Chem. 2020 Jan;95:103499. doi: 10.1016/j.bioorg.2019.103499. Epub 2019 Dec 6. Bioorg Chem. 2020. PMID: 31838287
-
Targeting acetylcholinesterase and butyrylcholinesterase in dementia.Int J Neuropsychopharmacol. 2006 Feb;9(1):101-24. doi: 10.1017/S1461145705005833. Epub 2005 Aug 5. Int J Neuropsychopharmacol. 2006. PMID: 16083515 Review.
-
[Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].Yao Xue Xue Bao. 2012 Mar;47(3):313-21. Yao Xue Xue Bao. 2012. PMID: 22645754 Review. Chinese.
Cited by
-
Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.Bioorg Chem. 2021 Mar;108:104681. doi: 10.1016/j.bioorg.2021.104681. Epub 2021 Jan 29. Bioorg Chem. 2021. PMID: 33571811 Free PMC article. Review.
-
In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.J Mol Model. 2018 Jun 5;24(7):151. doi: 10.1007/s00894-018-3696-6. J Mol Model. 2018. PMID: 29869722
-
Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors.Int J Mol Sci. 2022 Mar 14;23(6):3121. doi: 10.3390/ijms23063121. Int J Mol Sci. 2022. PMID: 35328542 Free PMC article. Review.
-
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease.J Cent Nerv Syst Dis. 2021 Jul 7;13:11795735211029113. doi: 10.1177/11795735211029113. eCollection 2021. J Cent Nerv Syst Dis. 2021. PMID: 34285627 Free PMC article. Review.
References
-
- Holmes C. Dementia. Medicine (Baltimore) 2012;40:628–31.
-
- Tartaglia MC, Vitali P, Migliaccio R, et al. Neuroimaging in dementia. Contin Lifelong Learn Neurol. 2010;16:153–75. - PubMed
-
- Akin JS, Dow WH, Lance PM, Loh CPA. Changes in access to health care in China, 1989–1997. Health Policy Plan. 2005;20:80–89. - PubMed
-
- Prince MJ. Dementia in China: East-west collaboration bears fruit. Lancet. 2013;381:1967–68. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical